Active Not Recruiting
PHASE3
INTERVENTIONAL
NCT04746924
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.
Interventions
Name:
Tislelizumab
Type:
DRUG
Description:
Tislelizumab is a monoclonal antibody formulated for intravenous injection.
Name:
Ociperlimab
Type:
DRUG
Description:
Ociperlimab is a monoclonal antibody formulated for intravenous injection.
Name:
Pembrolizumab
Type:
DRUG
Description:
Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
Name:
Placebo
Type:
DRUG
Description:
Placebo infusions will consist of a sterile, normal saline solution.
Primary Outcomes
Measure:
Overall Survival (OS)
TimeFrame:
Up to approximately 58 months
Description:
OS will be defined as the time from the date of randomization to the date of death due to any cause.
Trial Information
NCT ID
NCT04746924
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
BeiGene
Last Updated
December 15, 2025